Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Harris

Showing results (21-30 of 314) with videos related to

Pageof 32
Sort By:
Current Opinion in Nephrology and Hypertension|June 16, 2006
Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapyPeter C Harris, Vicente E Torres
Kidney360|July 7, 2023
Experimental Models of Polycystic Kidney Disease: Applications and Therapeutic TestingCynthia J Sieben, Peter C Harris
Nature Clinical Practice. Nephrology|August 26, 2006
Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseasesVicente E Torres, Peter C Harris
Journal of the American Society of Nephrology : JASN|May 18, 2018
The Underestimated Burden of Monogenic Diseases in Adult-Onset ESRDEmilie Cornec-Le Gall, Peter C Harris
Kidney International|July 23, 2015
A polycystin-centric view of cyst formation and disease: the polycystins revisitedAlbert C M Ong, Peter C Harris
Kidney International|March 23, 2005
Molecular pathogenesis of ADPKD: the polycystin complex gets complexAlbert C M Ong, Peter C Harris
Lancet (London, England)|April 17, 2007
Autosomal dominant polycystic kidney diseaseVicente E Torres, Peter C Harris, Yves Pirson
Urolithiasis|October 14, 2019
Correction to: Recent advances in the identification and management of inherited hyperoxaluriasDavid J Sas, Peter C Harris, Dawn S Milliner
Urolithiasis|December 12, 2018
Recent advances in the identification and management of inherited hyperoxaluriasDavid J Sas, Peter C Harris, Dawn S Milliner
Journal of the American Society of Nephrology : JASN|February 25, 2005
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK ratXiaofang Wang, Vincent Gattone, Peter C Harris, et al.
Pageof 32

Showing results (21-30 of 314) with videos related to

Sort By:
Pageof 32
Current Opinion in Nephrology and Hypertension|June 16, 2006
Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapyPeter C Harris, Vicente E Torres
Kidney360|July 7, 2023
Experimental Models of Polycystic Kidney Disease: Applications and Therapeutic TestingCynthia J Sieben, Peter C Harris
Nature Clinical Practice. Nephrology|August 26, 2006
Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseasesVicente E Torres, Peter C Harris
Journal of the American Society of Nephrology : JASN|May 18, 2018
The Underestimated Burden of Monogenic Diseases in Adult-Onset ESRDEmilie Cornec-Le Gall, Peter C Harris
Kidney International|July 23, 2015
A polycystin-centric view of cyst formation and disease: the polycystins revisitedAlbert C M Ong, Peter C Harris
Kidney International|March 23, 2005
Molecular pathogenesis of ADPKD: the polycystin complex gets complexAlbert C M Ong, Peter C Harris
Lancet (London, England)|April 17, 2007
Autosomal dominant polycystic kidney diseaseVicente E Torres, Peter C Harris, Yves Pirson
Urolithiasis|October 14, 2019
Correction to: Recent advances in the identification and management of inherited hyperoxaluriasDavid J Sas, Peter C Harris, Dawn S Milliner
Urolithiasis|December 12, 2018
Recent advances in the identification and management of inherited hyperoxaluriasDavid J Sas, Peter C Harris, Dawn S Milliner
Journal of the American Society of Nephrology : JASN|February 25, 2005
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK ratXiaofang Wang, Vincent Gattone, Peter C Harris, et al.
Pageof 32